This project is set within the context of the emergence of new blood-based biomarkers for neurodegenerative diseases, particularly Alzheimer’s disease (AD). The project objectives are to define reference intervals for blood biomarkers of AD in the adult population, to determine thresholds distinguishing normal from pathological values and to provide a normative basis for future clinical and epidemiological studies on neurodegenerative diseases. The results will document normal levels of AD biomarkers in the general population, will provide an essential foundation for the integration of these tests into prevention strategies, early diagnosis, and clinical research and will help inform public health decision-making and future clinical applications.
